Race Oncology Receives Ethics Approval for Phase 1 RC220 Trial

Race Oncology Ltd. ( (AU:RAC) ) has shared an update.

Race Oncology Ltd has received ethics approval from the Bellberry Human Research Ethics Committee to initiate a Phase 1 clinical trial of RC220 bisantrene, both alone and in combination with doxorubicin, for patients with solid tumors. This approval marks a significant milestone, enabling the company to begin patient enrollment at the Southside Cancer Care Centre in March 2025, with plans to expand to additional sites. The trial’s success could enhance Race Oncology’s position in the industry by advancing their cardioprotective cancer therapies, potentially benefiting stakeholders through improved treatment options.

More about Race Oncology Ltd.

Race Oncology Ltd is a biotechnology company focused on developing novel cancer therapies. The company specializes in creating cardioprotective treatments with anticancer benefits, aiming to improve patient outcomes in the oncology sector.

YTD Price Performance: -25.93%

Average Trading Volume: 80,528

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$183.3M

See more insights into RAC stock on TipRanks’ Stock Analysis page.